143 related articles for article (PubMed ID: 38112929)
41. [Preliminary efficacy analysis of Cheng's Giraffe reconstruction after proximal gastrectomy in adenocarcinoma of esophagogastric junction].
Cheng XD; Xu ZY; Du YA; Hu C; Yu JF; Yang LT; Huang L; Yu PF; Dai GG; Zhang YQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Feb; 23(2):158-162. PubMed ID: 32074796
[No Abstract] [Full Text] [Related]
42. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.
von Rahden BH; Stein HJ; Feith M; Becker K; Siewert JR
J Clin Oncol; 2005 Feb; 23(4):874-9. PubMed ID: 15681533
[TBL] [Abstract][Full Text] [Related]
43. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China.
Liu K; Feng F; Chen XZ; Zhou XY; Zhang JY; Chen XL; Zhang WH; Yang K; Zhang B; Zhang HW; Zhou ZG; Hu JK
Gastric Cancer; 2019 May; 22(3):506-517. PubMed ID: 30390154
[TBL] [Abstract][Full Text] [Related]
44. The prognostic relevance of parapyloric lymph node metastasis in Siewert type II/III adenocarcinoma of the esophagogastric junction.
Wang JB; Lin MQ; Li P; Xie JW; Lin JX; Lu J; Chen QY; Cao LL; Lin M; Zheng CH; Huang CM
Eur J Surg Oncol; 2017 Dec; 43(12):2333-2340. PubMed ID: 28928013
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of systemic inflammation response index and platelet-lymphocyte ratio in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer.
Fang T; Yin X; Wang Y; Zhang L; Yang S; Jiang X; Xue Y
Heliyon; 2024 Feb; 10(4):e26176. PubMed ID: 38420481
[TBL] [Abstract][Full Text] [Related]
46. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.
Du R; Ming J; Geng J; Zhu X; Zhang Y; Li S; Liu Z; Wang H; Wang Z; Tang L; Zhang X; Wu A; Bu Z; Yan Y; Li Z; Li Y; Li Z; Wang W
Radiat Oncol; 2022 Mar; 17(1):45. PubMed ID: 35241109
[TBL] [Abstract][Full Text] [Related]
47. Influence of Primary Tumor Resection on Survival of Patients With Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis.
Chen J; Jia X; Chen H; Cai J; Chen L
Cancer Control; 2023; 30():10732748231208313. PubMed ID: 37851478
[TBL] [Abstract][Full Text] [Related]
48. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma.
Lee IS; Ahn JY; Yook JH; Kim BS
World J Surg Oncol; 2017 Jan; 15(1):28. PubMed ID: 28100248
[TBL] [Abstract][Full Text] [Related]
49. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer.
Tamandl D; Paireder M; Asari R; Baltzer PA; Schoppmann SF; Ba-Ssalamah A
Eur Radiol; 2016 May; 26(5):1359-67. PubMed ID: 26334504
[TBL] [Abstract][Full Text] [Related]
50. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
51. Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation.
Liu F; Zhou R; Jiang F; Liu G; Li K; Zhu G
Ann Surg Oncol; 2019 May; 26(5):1292-1300. PubMed ID: 30805805
[TBL] [Abstract][Full Text] [Related]
52. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G
Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of preoperative albumin-to-globulin ratio and prognostic nutritional index combined score in Siewert type 3 adenocarcinoma of esophagogastric junction.
Wang Y; Zhu Z; Li C; Ma Y; You Q; Li Z; Zhang H; Song H; Xue Y
Cancer Manag Res; 2019; 11():7631-7638. PubMed ID: 31616179
[TBL] [Abstract][Full Text] [Related]
54. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?
Blank S; Schmidt T; Heger P; Strowitzki MJ; Sisic L; Heger U; Nienhueser H; Haag GM; Bruckner T; Mihaljevic AL; Ott K; Büchler MW; Ulrich A
Gastric Cancer; 2018 Mar; 21(2):303-314. PubMed ID: 28685209
[TBL] [Abstract][Full Text] [Related]
55. [Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].
Wu LL; Cai MZ; Wang BG; Deng JY; Ke B; Zhang RP; Liang H; Wang XN
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):680-688. PubMed ID: 37583026
[No Abstract] [Full Text] [Related]
56. Impact of the Ratio of Visceral Fat Area (VFA) to Psoas Muscle Area (PMA) (V/P Ratio) on Survival for Surgically Resected Esophageal Cancer.
Sakai M; Sohda M; Uchida S; Yamaguchi A; Watanabe T; Saito H; Ubukata Y; Nakazawa N; Kuriyama K; Sano A; Ogawa H; Yokobori T; Shirabe K; Saeki H
Ann Surg Oncol; 2022 Mar; ():. PubMed ID: 35258768
[TBL] [Abstract][Full Text] [Related]
57. [Surgical strategy for adenocarcinoma of esophagogastric junction].
Lu Y; Zhang K; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):107-111. PubMed ID: 30799532
[TBL] [Abstract][Full Text] [Related]
58. Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers.
Chakedis J; Spolverato G; Beal EW; Woelfel I; Bagante F; Merath K; Sun SH; Chafitz A; Galo J; Dillhoff M; Cloyd J; Pawlik TM
J Gastrointest Surg; 2018 Oct; 22(10):1697-1708. PubMed ID: 29855867
[TBL] [Abstract][Full Text] [Related]
59. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
60. Can Clinical Stage in the 8
Watanabe H; Hasegawa S; Kumazu Y; Hashimoto I; Komori K; Suematsu H; Kano K; Fujikawa H; Aoyama T; Yamada T; Yukawa N; Yoshikawa T; Rino Y; Saito A; Ogata T; Oshima T
In Vivo; 2023; 37(4):1790-1796. PubMed ID: 37369497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]